Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus enoxaparin for thromboprophylaxis after elective total knee replacement
NL-OMON30891Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2007
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing Apixaban arm with Enoxaparin arm (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Aug 2007; status: active, not recruiting.
02
Drugs
apixabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON30891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30891.